Rocket Pharmaceuticals (RCKT) grants GC RSUs and 468,187-share option

Rhea-AI Filing Summary

Rocket Pharmaceuticals General Counsel Martin Wilson received new equity awards. On February 11, 2026, he was granted 311,813 shares of common stock in the form of restricted stock units at a price of $0 per share, bringing his directly held common stock (including RSUs) to 695,629 shares.

He was also granted a stock option for 468,187 shares at an exercise price of $3.24 per share, expiring February 11, 2036. One-third of both the RSUs and the option will vest on February 11, 2027, with the remaining portions vesting in equal quarterly installments over the following two years, contingent on continued employment.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Wilson Martin

Role General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	468,187	$0.00	--
Grant/Award	Common Stock	311,813	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 468,187 shares (Direct); Common Stock — 695,629 shares (Direct)

Footnotes (1)

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years. This option represents a right to purchase a total of 468,187 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wilson Martin

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NJ 08512

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	02/11/2026		A		311,813(2)	A	$0	695,629(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.24	02/11/2026		A		468,187		(3)	02/11/2036	Common Stock	468,187	$0	468,187	D

Explanation of Responses:

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

2. Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.

3. This option represents a right to purchase a total of 468,187 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

	/s/ Martin Louis Wilson	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Rocket Pharmaceuticals (RCKT) grant to its General Counsel?

Rocket Pharmaceuticals granted General Counsel Martin Wilson 311,813 restricted stock units and a stock option for 468,187 shares. The RSUs were granted at $0 per share, while the option has a $3.24 exercise price and a 10-year term ending February 11, 2036.

How do the RSUs granted to Rocket Pharmaceuticals (RCKT) General Counsel vest?

The 311,813 RSUs granted to the General Counsel vest over three years. One-third becomes fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to his continued employment with the company.

What are the key terms of the stock option granted by Rocket Pharmaceuticals (RCKT)?

The stock option covers 468,187 shares of common stock at a $3.24 exercise price. One-third vests and becomes exercisable on February 11, 2027, with the rest vesting in equal quarterly installments over two years, expiring February 11, 2036.

How many Rocket Pharmaceuticals (RCKT) shares does the General Counsel own after these grants?

After the February 11, 2026 grants, the General Counsel beneficially owns 695,629 shares of Rocket Pharmaceuticals common stock directly. This figure includes restricted stock units that convert into common stock on a one-for-one basis, as described in the filing footnotes.

Were the Rocket Pharmaceuticals (RCKT) equity awards to the General Counsel purchases or grants?

The equity awards were grants, not open-market purchases. Both the RSUs and the stock option are reported with transaction code "A," indicating a grant, award, or other acquisition, with a price of $0 for the RSUs and a fixed exercise price for the option.

What conditions affect vesting of Rocket Pharmaceuticals (RCKT) General Counsel’s option grant?

Vesting of the 468,187-share stock option depends on continued employment with Rocket Pharmaceuticals. One-third vests on February 11, 2027, and the remainder vests in equal quarterly installments over the following two years, as long as he remains employed by the issuer.